A single dose of tranexamic acid reduces blood loss after reverse and anatomic shoulder arthroplasty: a randomized controlled trial

BackgroundHematoma formation and the need for blood transfusions are commonly reported complications after shoulder arthroplasty. Tranexamic acid (TXA) has been widely used in hip knee arthroplasty to decrease perioperative loss. The role of TXA is still being established arthroplasty.Materials methodsWe conducted a double-blind randomized controlled trial comparing intravenous vs. placebo 60 patients undergoing primary anatomic or reverse Of these patients, 29 received whereas 31 single dose 2 g TXA. Patient demographic characteristics, as well drain tube output, loss, hematoma formation, transfusion requirement, length hospital stay, pain score, were recorded. Patients followed up 12 weeks assess complications.ResultsPatients who had lower output at all time points: 41 mL 133 6 hours, 75 179 94 226 24 hours (P < .001 all). They also higher postoperative hemoglobin (Hb) level (12.3 g/dL 11.4 g/dL, P = .009), change Hb (1.7 2.3 .011), total loss (0.078 0.103 g, .042), volume (0.55 L 0.74 L, .021), hematocrit (36.7% 34.6%, .020), (5.4% 7.6%, .022). There was no significant difference score required transfusion.ConclusionA decreases shoulder. No differences detected occurrence complications, transfusion, stay. With mounting evidence now available, elective should be given Hematoma We complications. transfusion. A